Arcus Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Arcus Biosciences, Inc. on October 19, 2018. The report discloses a corporate governance event regarding the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and compensation arrangements.
Material Changes
The Board of Directors increased its size from five (5) to six (6) directors. Kristen M. Hege, M.D., was appointed to fill the newly created vacancy as a Class I director.
Compensation and Governance Details
- Annual Cash Retainer: $35,000 for Dr. Hege as a non-employee director.
- Equity Grant: Option to purchase 35,000 shares of common stock.
- Vesting Schedule: Substantially equal monthly installments over 36 months of continuous service.
- Acceleration: Vesting accelerates in the event of a Change in Control.
- Related Party Transactions: No transactions requiring disclosure under Item 404(a) of Regulation S-K exist between Dr. Hege and the Company.
Investor Verification Checklist
- Verify the total number of directors on the Board following the increase to six.
- Confirm the vesting terms and exercise price of the 35,000 share option granted to Dr. Hege.
- Review the Company's Compensation Program for Non-Employee Directors to understand Change in Control definitions.
- Check subsequent filings for any changes to the Board composition or Dr. Hege's tenure.